Neuland Laboratories Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 30, 2025. Further, the company has informed the Exchange regarding voting results along with copy of scrutinizers report together with the proceedings of the meeting.
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Neuland Laboratories held its 41st AGM on July 30, 2025, via video conferencing, where all 7 resolutions were passed with the required majority. Shareholders approved the audited financial statements for FY25 and a final dividend of Rs. 12 per share (120% on face value of Rs. 10). Re-appointments of Dr. Christopher M. Cimarusti as Director and Mr. Davuluri Saharsh Rao as Vice Chairman & Managing Director were also approved, along with the appointment of the Secretarial Auditor and ratification of Cost Auditor remuneration. Out of 46,122 shareholders on record, 76 attended the meeting, and around 63.7% of outstanding shares were voted. Most resolutions passed with near-unanimous support, but the re-appointment of Mr. Davuluri Saharsh Rao as Vice Chairman & Managing Director saw notable dissent of 13.07% from public institutional investors, while the rest of the resolutions had less than 1% dissent.
The approval of a Rs. 12 per share dividend is a positive for shareholders, confirming continued returns from the company. The 13% dissent from institutional investors on the executive director re-appointment is worth monitoring but the resolution still passed comfortably, so no immediate governance concern for the stock.